266 related articles for article (PubMed ID: 30446569)
1. IL-33 Released in the Liver Inhibits Tumor Growth via Promotion of CD4
Jin Z; Lei L; Lin D; Liu Y; Song Y; Gong H; Zhu Y; Mei Y; Hu B; Wu Y; Zhang G; Liu H
J Immunol; 2018 Dec; 201(12):3770-3779. PubMed ID: 30446569
[TBL] [Abstract][Full Text] [Related]
2. NKT and CD8 lymphocytes mediate suppression of hepatocellular carcinoma growth via tumor antigen-pulsed dendritic cells.
Shibolet O; Alper R; Zlotogarov L; Thalenfeld B; Engelhardt D; Rabbani E; Ilan Y
Int J Cancer; 2003 Aug; 106(2):236-43. PubMed ID: 12800200
[TBL] [Abstract][Full Text] [Related]
3. Antitumour activity mediated by CD4+ cytotoxic T lymphocytes against MHC class II-negative mouse hepatocellular carcinoma induced by dendritic cell vaccine and interleukin-12.
Homma S; Komita H; Sagawa Y; Ohno T; Toda G
Immunology; 2005 Aug; 115(4):451-61. PubMed ID: 16011514
[TBL] [Abstract][Full Text] [Related]
4. Tc1 and Tc2 effector cell therapy elicit long-term tumor immunity by contrasting mechanisms that result in complementary endogenous type 1 antitumor responses.
Dobrzanski MJ; Reome JB; Hollenbaugh JA; Dutton RW
J Immunol; 2004 Feb; 172(3):1380-90. PubMed ID: 14734713
[TBL] [Abstract][Full Text] [Related]
5. Combination of SLC administration and Tregs depletion is an attractive strategy for targeting hepatocellular carcinoma.
Chen L; Zhou S; Qin J; Hu H; Ma H; Liu B; Wang X; Ma J; Ye S; Zhong C; Zhou G; Liang C
Mol Cancer; 2013 Dec; 12(1):153. PubMed ID: 24304581
[TBL] [Abstract][Full Text] [Related]
6. Interferon-gamma produced by interleukin-12-activated tumor infiltrating CD8+T cells directly induces apoptosis of mouse hepatocellular carcinoma.
Komita H; Homma S; Saotome H; Zeniya M; Ohno T; Toda G
J Hepatol; 2006 Nov; 45(5):662-72. PubMed ID: 16935390
[TBL] [Abstract][Full Text] [Related]
7. Role of effector cell-derived IL-4, IL-5, and perforin in early and late stages of type 2 CD8 effector cell-mediated tumor rejection.
Dobrzanski MJ; Reome JB; Dutton RW
J Immunol; 2001 Jul; 167(1):424-34. PubMed ID: 11418679
[TBL] [Abstract][Full Text] [Related]
8. IL-7 inhibits tumor growth by promoting T cell-mediated antitumor immunity in Meth A model.
Tang JC; Shen GB; Wang SM; Wan YS; Wei YQ
Immunol Lett; 2014; 158(1-2):159-66. PubMed ID: 24406503
[TBL] [Abstract][Full Text] [Related]
9. Suppression of hepatocellular carcinoma by transplantation of ex-vivo immune-modulated NKT lymphocytes.
Margalit M; Shibolet O; Klein A; Elinav E; Alper R; Thalenfeld B; Engelhardt D; Rabbani E; Ilan Y
Int J Cancer; 2005 Jun; 115(3):443-9. PubMed ID: 15688366
[TBL] [Abstract][Full Text] [Related]
10. Increased Expression of sST2 in Early HIV Infected Patients Attenuated the IL-33 Induced T Cell Responses.
Wu X; Li Y; Song CB; Chen YL; Fu YJ; Jiang YJ; Ding HB; Shang H; Zhang ZN
Front Immunol; 2018; 9():2850. PubMed ID: 30564243
[TBL] [Abstract][Full Text] [Related]
11. alpha-fetoprotein and interleukin-18 gene-modified dendritic cells effectively stimulate specific type-1 CD4- and CD8-mediated T-Cell response from hepatocellular carcinoma patients in Vitro.
Cao DY; Yang JY; Dou KF; Ma LY; Teng ZH
Hum Immunol; 2007 May; 68(5):334-41. PubMed ID: 17462500
[TBL] [Abstract][Full Text] [Related]
12. In drug-induced, immune-mediated hepatitis, interleukin-33 reduces hepatitis and improves survival independently and as a consequence of FoxP3+ T-cell activity.
Cottagiri M; Nyandjo M; Stephens M; Mantilla JJ; Saito H; Mackay IR; Rose NR; Njoku DB
Cell Mol Immunol; 2019 Aug; 16(8):706-717. PubMed ID: 30030493
[TBL] [Abstract][Full Text] [Related]
13. CD4 T cells inhibit in vivo the CD8-mediated immune response against murine colon carcinoma cells transduced with interleukin-12 genes.
Martinotti A; Stoppacciaro A; Vagliani M; Melani C; Spreafico F; Wysocka M; Parmiani G; Trinchieri G; Colombo MP
Eur J Immunol; 1995 Jan; 25(1):137-46. PubMed ID: 7843224
[TBL] [Abstract][Full Text] [Related]
14. Regression of engineered myeloma cells secreting interferon-gamma-inducing factor is mediated by both CD4(+)/CD8(+) T and natural killer cells.
Xiang J; Chen Z; Huang H; Moyana T
Leuk Res; 2001 Oct; 25(10):909-15. PubMed ID: 11532525
[TBL] [Abstract][Full Text] [Related]
15. Tumoral expression of IL-33 inhibits tumor growth and modifies the tumor microenvironment through CD8+ T and NK cells.
Gao X; Wang X; Yang Q; Zhao X; Wen W; Li G; Lu J; Qin W; Qi Y; Xie F; Jiang J; Wu C; Zhang X; Chen X; Turnquist H; Zhu Y; Lu B
J Immunol; 2015 Jan; 194(1):438-45. PubMed ID: 25429071
[TBL] [Abstract][Full Text] [Related]
16. Critical role of IL-33 receptor ST2 in experimental cerebral malaria development.
Palomo J; Reverchon F; Piotet J; Besnard AG; Couturier-Maillard A; Maillet I; Tefit M; Erard F; Mazier D; Ryffel B; Quesniaux VF
Eur J Immunol; 2015 May; 45(5):1354-65. PubMed ID: 25682948
[TBL] [Abstract][Full Text] [Related]
17. IL-12 augments CD8+ T cell development for contact hypersensitivity responses and circumvents anti-CD154 antibody-mediated inhibition.
Gorbachev AV; DiIulio NA; Fairchild RL
J Immunol; 2001 Jul; 167(1):156-62. PubMed ID: 11418644
[TBL] [Abstract][Full Text] [Related]
18. Decreased expression of interleukin-36α correlates with poor prognosis in hepatocellular carcinoma.
Pan QZ; Pan K; Zhao JJ; Chen JG; Li JJ; Lv L; Wang DD; Zheng HX; Jiang SS; Zhang XF; Xia JC
Cancer Immunol Immunother; 2013 Nov; 62(11):1675-85. PubMed ID: 24061617
[TBL] [Abstract][Full Text] [Related]
19. Gene therapy with CX3CL1/Fractalkine induces antitumor immunity to regress effectively mouse hepatocellular carcinoma.
Tang L; Hu HD; Hu P; Lan YH; Peng ML; Chen M; Ren H
Gene Ther; 2007 Aug; 14(16):1226-34. PubMed ID: 17597794
[TBL] [Abstract][Full Text] [Related]
20. Development of CD8+ effector T cells is differentially regulated by IL-18 and IL-12.
Okamoto I; Kohno K; Tanimoto T; Ikegami H; Kurimoto M
J Immunol; 1999 Mar; 162(6):3202-11. PubMed ID: 10092771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
